134 related articles for article (PubMed ID: 9425445)
1. Anti-HIV genetic treatment of antigen-specific human CD4 lymphocytes for adoptive immunotherapy of opportunistic infections in AIDS.
Manca F; Fenoglio D; Franchin E; Saverino D; Li Pira G; Buffa F; Bignardi D; Del Pup L; Palù G
Gene Ther; 1997 Nov; 4(11):1216-24. PubMed ID: 9425445
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of simian/human immunodeficiency virus replication in CD4+ T cells derived from lentiviral-transduced CD34+ hematopoietic cells.
Braun SE; Wong FE; Connole M; Qiu G; Lee L; Gillis J; Lu X; Humeau L; Slepushkin V; Binder GK; Dropulic B; Johnson RP
Mol Ther; 2005 Dec; 12(6):1157-67. PubMed ID: 16168713
[TBL] [Abstract][Full Text] [Related]
3. Long-term protection against HIV-1 infection conferred by tat or rev antisense RNA was affected by the design of the retroviral vector.
Peng H; Callison D; Li P; Burrell C
Virology; 1996 Jun; 220(2):377-89. PubMed ID: 8661389
[TBL] [Abstract][Full Text] [Related]
4. Antitat gene therapy: a candidate for late-stage AIDS patients.
Lisziewicz J; Sun D; Lisziewicz A; Gallo RC
Gene Ther; 1995 May; 2(3):218-22. PubMed ID: 7614253
[TBL] [Abstract][Full Text] [Related]
5. Genetically modified immunocompetent cells in HIV infection.
Palù G; Li Pira G; Gennari F; Fenoglio D; Parolin C; Manca F
Gene Ther; 2001 Nov; 8(21):1593-600. PubMed ID: 11894997
[TBL] [Abstract][Full Text] [Related]
6. Long-term survival and concomitant gene expression of ribozyme-transduced CD4+ T-lymphocytes in HIV-infected patients.
Macpherson JL; Boyd MP; Arndt AJ; Todd AV; Fanning GC; Ely JA; Elliott F; Knop A; Raponi M; Murray J; Gerlach W; Sun LQ; Penny R; Symonds GP; Carr A; Cooper DA
J Gene Med; 2005 May; 7(5):552-64. PubMed ID: 15655805
[TBL] [Abstract][Full Text] [Related]
7. Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha.
Willemsen R; Ronteltap C; Heuveling M; Debets R; Bolhuis R
Gene Ther; 2005 Jan; 12(2):140-6. PubMed ID: 15496961
[TBL] [Abstract][Full Text] [Related]
8. High transdominant RevM10 protein levels are required to inhibit HIV-1 replication in cell lines and primary T cells: implication for gene therapy of AIDS.
Plavec I; Agarwal M; Ho KE; Pineda M; Auten J; Baker J; Matsuzaki H; Escaich S; Bonyhadi M; Böhnlein E
Gene Ther; 1997 Feb; 4(2):128-39. PubMed ID: 9081703
[TBL] [Abstract][Full Text] [Related]
9. Ex vivo transduction and expansion of CD4+ lymphocytes from HIV + donors: prelude to a ribozyme gene therapy trial.
Leavitt MC; Yu M; Wong-Staal F; Looney DJ
Gene Ther; 1996 Jul; 3(7):599-606. PubMed ID: 8818647
[TBL] [Abstract][Full Text] [Related]
10. High level inhibition of HIV replication with combination RNA decoys expressed from an HIV-Tat inducible vector.
Fraisier C; Irvine A; Wrighton C; Craig R; Dzierzak E
Gene Ther; 1998 Dec; 5(12):1665-76. PubMed ID: 10023446
[TBL] [Abstract][Full Text] [Related]
11. Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys.
Maggiorella MT; Baroncelli S; Michelini Z; Fanales-Belasio E; Moretti S; Sernicola L; Cara A; Negri DR; Buttò S; Fiorelli V; Tripiciano A; Scoglio A; Caputo A; Borsetti A; Ridolfi B; Bona R; ten Haaft P; Macchia I; Leone P; Pavone-Cossut MR; Nappi F; Ciccozzi M; Heeney J; Titti F; Cafaro A; Ensoli B
Vaccine; 2004 Sep; 22(25-26):3258-69. PubMed ID: 15308348
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of HIV-1 replication by an anti-tat hammerhead ribozyme.
Jackson WH; Moscoso H; Nechtman JF; Galileo DS; Garver FA; Lanclos KD
Biochem Biophys Res Commun; 1998 Apr; 245(1):81-4. PubMed ID: 9535787
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of HIV-1 replication by a Tat transdominant negative mutant in human peripheral blood lymphocytes from healthy donors and HIV-1-infected patients.
Rossi C; Balboni PG; Betti M; Marconi PC; Bozzini R; Grossi MP; Barbanti-Brodano G; Caputo A
Gene Ther; 1997 Nov; 4(11):1261-9. PubMed ID: 9425451
[TBL] [Abstract][Full Text] [Related]
14. MLV-derived retroviral vectors selective for CD4-expressing cells and resistant to neutralization by sera from HIV-infected patients.
Stitz J; Steidl S; Merget-Millitzer H; König R; Müller P; Nocken F; Engelstädter M; Bobkova M; Schmitt I; Kurth R; Buchholz CJ; Cichutek K
Virology; 2000 Feb; 267(2):229-36. PubMed ID: 10662618
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of HIV-1 replication in primary human T cells transduced with an intracellular anti-HIV-1 p17 antibody gene.
Tewari D; Notkins AL; Zhou P
J Gene Med; 2003 Mar; 5(3):182-9. PubMed ID: 12666184
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of HIV-1 replication by novel lentiviral vectors expressing transdominant Rev and HIV-1 env antisense.
Mautino MR; Morgan RA
Gene Ther; 2002 Apr; 9(7):421-31. PubMed ID: 11938457
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of HIV-1 replication in chronically infected cell lines and peripheral blood mononuclear cells by retrovirus-mediated antitat gene transfer.
Li Y; Starr SE; Lisziewicz J; Ho WZ
Gene Ther; 2000 Feb; 7(4):321-8. PubMed ID: 10694813
[TBL] [Abstract][Full Text] [Related]
18. Increased gene transfer into human CD34+ progenitor cells using retroviral vectors produced by a canine packaging cell line.
Bauer G; Sauter S; Ibanez C; Rice CR; Valdez P; Jolly D; Kohn DB
Biol Blood Marrow Transplant; 1998; 4(3):119-27. PubMed ID: 9923409
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor.
Roszkowski JJ; Lyons GE; Kast WM; Yee C; Van Besien K; Nishimura MI
Cancer Res; 2005 Feb; 65(4):1570-6. PubMed ID: 15735047
[TBL] [Abstract][Full Text] [Related]
20. Immunoprevalence of the CD4+ T-cell response to HIV Tat and Vpr proteins is provided by clustered and disperse epitopes, respectively.
Castelli FA; Houitte D; Munier G; Szely N; Lecoq A; Briand JP; Muller S; Maillere B
Eur J Immunol; 2008 Oct; 38(10):2821-31. PubMed ID: 18828138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
